Glucosado Braun

Glucosado Braun is a sterile aqueous solution for injection that contains glucose monohydrate as its active ingredient. The product is supplied in an unspecified strength and is intended for intravenous administration. It is classified as a parenteral carbohydrate used in the European Union market for medical purposes under prescription. Glucosado Braun provides exogenous glucose to support cellular energy metabolism and to help maintain plasma glucose levels.

Glucosado Braun is employed in clinical settings where rapid glucose supplementation or fluid replacement is required.

- Treatment of acute hypoglycemia when oral intake is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in perioperative or critical‑care environments. - Support of carbohydrate needs during prolonged fasting or surgical procedures. - Maintenance of plasma glucose concentration in patients receiving insulin therapy.

Adverse reactions to Glucosado Braun are generally related to the intravenous administration of a carbohydrate solution.

Common: - Mild hyperglycemia, especially when administered in large volumes. - Local irritation or pain at the injection site. - Nausea or transient vomiting. - Electrolyte imbalance such as mild hyponatremia.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic or anaphylactic reaction manifested by rash, itching, or respiratory distress. - Volume overload causing pulmonary edema in patients with compromised cardiac function.

When using Glucosado Braun, clinicians should observe several precautions to minimize risks and ensure appropriate therapy.

- Assess blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or hepatic impairment. - Monitor fluid balance closely in individuals at risk for volume overload. - Use caution in patients with known hypersensitivity to glucose solutions. - Avoid rapid administration in neonates and infants due to metabolic instability. - Review electrolyte status, particularly sodium and potassium, before initiating therapy.

Glucosado Braun may interact with other agents that affect glucose metabolism or fluid balance.

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring. - Co‑administration with other hyperosmolar dextrose solutions. - Use with catecholamine infusions that can increase glucose production without adequate monitoring.

Use with caution: - Concurrent diuretics that may exacerbate electrolyte shifts. - Vasopressor agents in patients with compromised cardiac function. - Parenteral nutrition mixtures containing other carbohydrates; adjust total carbohydrate load.